KR20120116401A - 장기-작용성의 주사가능한 팔리페리돈 에스테르와 관련된 투약 요법 - Google Patents

장기-작용성의 주사가능한 팔리페리돈 에스테르와 관련된 투약 요법 Download PDF

Info

Publication number
KR20120116401A
KR20120116401A KR1020127013546A KR20127013546A KR20120116401A KR 20120116401 A KR20120116401 A KR 20120116401A KR 1020127013546 A KR1020127013546 A KR 1020127013546A KR 20127013546 A KR20127013546 A KR 20127013546A KR 20120116401 A KR20120116401 A KR 20120116401A
Authority
KR
South Korea
Prior art keywords
dose
patient
paliperidone palmitate
paliperidone
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127013546A
Other languages
English (en)
Korean (ko)
Inventor
피터 에이치. 레윈-브리스코
메이어 크리스티아나 가스만
스리하리 고팔
데이비드 더블유. 허프
바트 엠. 엠. 레메리에
마헤쉬 엔. 삼타니
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43302985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20120116401(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20120116401A publication Critical patent/KR20120116401A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020127013546A 2009-10-30 2010-10-29 장기-작용성의 주사가능한 팔리페리돈 에스테르와 관련된 투약 요법 Ceased KR20120116401A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25669609P 2009-10-30 2009-10-30
US61/256,696 2009-10-30

Publications (1)

Publication Number Publication Date
KR20120116401A true KR20120116401A (ko) 2012-10-22

Family

ID=43302985

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127013546A Ceased KR20120116401A (ko) 2009-10-30 2010-10-29 장기-작용성의 주사가능한 팔리페리돈 에스테르와 관련된 투약 요법

Country Status (12)

Country Link
US (2) US20110105536A1 (enExample)
EP (1) EP2493473A1 (enExample)
JP (2) JP2013509435A (enExample)
KR (1) KR20120116401A (enExample)
CN (1) CN102802631A (enExample)
AU (2) AU2010313290A1 (enExample)
BR (1) BR112012010195A2 (enExample)
CA (1) CA2742393A1 (enExample)
CL (1) CL2012001110A1 (enExample)
MX (1) MX2012005083A (enExample)
NZ (1) NZ599558A (enExample)
WO (1) WO2011053829A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170134583A (ko) * 2015-04-07 2017-12-06 얀센 파마슈티칼즈, 인코포레이티드 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CA2655335C (en) 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
EP2547206B1 (en) 2010-03-15 2016-05-11 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
ES2972387T3 (es) 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN114728134A (zh) 2019-09-25 2022-07-08 杨森制药公司 药物施用系统的互连
WO2022049006A1 (en) * 2020-09-02 2022-03-10 Janssen Pharmaceutica Nv Pre-filled syringe with optimized stopper placement
EP4025188B1 (en) * 2020-11-30 2024-01-10 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
SI4025187T1 (sl) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem
CN116528836A (zh) 2020-11-30 2023-08-01 詹森药业有限公司 与延长释放帕潘立酮可注射制剂相关的给药方案
US20240148641A1 (en) * 2021-03-17 2024-05-09 Medincell S.A. Long Acting Injectable Formulation Comprising Risperidone and Biodegradable Polymers
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
KR100338776B1 (ko) 2000-07-11 2002-05-31 윤종용 멀티 로우 어드레스 테스트 가능한 반도체 메모리 장치 및그 테스트 방법
CN101163702B (zh) 2005-04-25 2011-09-07 詹森药业有限公司 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
US20070197591A1 (en) * 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
JP2009524685A (ja) * 2006-08-14 2009-07-02 テバ ファーマシューティカル インダストリーズ リミティド ９−ヒドロキシ−リスペリドン（パリペリドン）の結晶型
CA2655335C (en) 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170134583A (ko) * 2015-04-07 2017-12-06 얀센 파마슈티칼즈, 인코포레이티드 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획
KR20230162162A (ko) * 2015-04-07 2023-11-28 잔센파마슈티카엔.브이. 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획

Also Published As

Publication number Publication date
EP2493473A1 (en) 2012-09-05
JP2016102123A (ja) 2016-06-02
AU2010313290A1 (en) 2012-05-17
US20110105536A1 (en) 2011-05-05
JP2013509435A (ja) 2013-03-14
BR112012010195A2 (pt) 2016-04-26
NZ599558A (en) 2014-09-26
CA2742393A1 (en) 2011-05-05
AU2015243103A1 (en) 2015-11-05
MX2012005083A (es) 2012-09-28
CN102802631A (zh) 2012-11-28
CL2012001110A1 (es) 2012-10-19
WO2011053829A1 (en) 2011-05-05
US20130331402A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
US20110105536A1 (en) Dosing regimen associated with long-acting injectable paliperidone esters
AU2008340101C1 (en) Dosing regimen associated with long acting injectable paliperidone esters
JP2024503463A (ja) 薬剤投与用の経皮浸透製剤
RU2627469C2 (ru) Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбита
EP3744326B1 (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
KR20230116837A (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
KR20230116836A (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
Yin et al. Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers
KR20240049580A (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
HK40110149A (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK40044495B (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK40044495A (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK40064072A (en) Dosing regimen associated with long acting injectable paliperidone esters
WO2025093572A1 (en) Solid dispersion compositions and uses thereof
HK1249047B (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
WO2016003886A1 (en) 4-aminoquinoline compositions and methods for using same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120525

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151028

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160725

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161121

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160725

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I